icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Substantial
Substantial in the treatment of SJIA.
Clinical Added Value
moderate
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.
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
zcQEaPpB0hGkYaeH